ここから本文です。

Update:February 24, 2021

Remarks from Our Director

Japanese

Hiroki Nagase

When Chiba Cancer Center was established in 1972, the Chiba Prefectural Government also included plans for the Chiba Cancer Center Research Institute (CCCRI) as part of the solution to cancer treatment. Following our last 48 years of achievements, CCCRI continues to move forward with new endeavors to innovate for cancer patients, paving the steps towards a new vision of Chiba Cancer Center as a comprehensive cancer center to transform benchside research to healthcare professionals in the hospital. We strive to eradicate cancer in Chiba by generating new knowledge and integrating breakthrough research with graduate medical education. We work hard to actualize personalized medicine for cancer patients and community care with mind-and-body support through our continuing research effort.

Since November of 1972, in addition to support from the prefectural government, CCCRI was also the recipient of substantial research grants from agencies such as the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Ministry of Health, Labour and Welfare (MHLW), Japan Agency for Medical Research and Development (AMED) and so on. CCCRI retain its status as a premier research institute while representing the third oldest public comprehensive cancer center in Japan.

CCCRI has grown to be one of the world’s foremost cancer research organizations, with our distinguished records of achievement and recognition in elucidating the genetic basis of cancer and phasing in a new era of drug discovery. We continue to place a uniquely dedicated focus on translational science and clinical opportunities, developing molecularly targeted therapies and tumor organoid model for drug screening. Recently through a mutual collaboration among CCCRI, Chiba University, Nihon University and Kyoto University, we have developed a platform of generating therapeutic candidates targeting genetic and epigenetic mutations in cancer. We also recently added new faculties to strengthen research in immunotherapy and artificial intelligence (AI) against cancer. CCCRI continues to invest significant effort in the development of precision medicine, Cancer Biobank, population-based cancer registry to serve the over 6.2 million people in Chiba. Our work shall provide high quality translational research, together via advances in Big Data to facilitate research in cancer epidemiology. We have been taking steps forward in facilitating new discoveries that will lead to improvements in prevention, diagnosis and treatment for cancer patients, and frankly we are excited to see our success come to fruition!

Hiroki Nagase

Hiroki Nagase, M.D., Ph.D.
Director, Chiba Cancer Center Research Institute (CCCRI)